OMER EQUITY ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation - OMER

NEW YORK, Oct. 7, 2021 /PRNewswire/ --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Omeros Corporation (NASDAQ: OMER) resulting from allegations that Omeros may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Omeros securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://www.rosenlegal.com/cases-register-2167.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On October 1, 2021, Omeros announced that the U.S. Food and Drug Administration ("FDA") had identified deficiencies with the Company's Biologics License Application for its drug candidate narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), which "preclude discussion of labeling and post-marketing requirements/commitments at this time." The Company further advised that the "FDA did not provide specific details of the deficiencies in its notification[,]" and that the "the company does not currently expect any resolution to occur by the October 17, 2021 target action date under the Prescription Drug User Fee Act (PDUFA)."

On this news, Omeros's stock price fell $5.25 per share, or 38.07%, to close at $8.54 per share on October 1, 2021.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      cases@rosenlegal.com
      www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/omer-equity-alert-rosen-leading-investor-counsel-encourages-omeros-corporation-investors-with-losses-to-inquire-about-class-action-investigation--omer-301395806.html

SOURCE Rosen Law Firm, P.A.